Core Viewpoint - Sanyou Medical (688085.SH) announced that two shareholders, Xu Nong and Michael Mingyan Liu, plan to reduce their holdings due to personal financial needs, with a total reduction of up to 6,669,249 shares, representing 2.00% of the company's total share capital [1] Group 1 - Xu Nong intends to reduce his indirect holdings through Chao Dong Tian Cheng No. 18 by up to 2,212,155 shares, accounting for 0.66% of the total share capital [1] - Michael Mingyan Liu plans to reduce his holdings by up to 4,457,094 shares, which represents 1.34% of the total share capital [1] - The reduction will take place within three months starting from February 4, 2026, and will be subject to a limit of 2.00% of the total share capital for any continuous 90-day period [1]

证券代码：688085 证券简称：三友医疗 公告编号：2026-001 上海三友医疗器械股份有限公司 关于实际控制人及一致行动人减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 减持计划的主要内容 近日，公司收到徐农先生及 Michael Mingyan Liu（刘明岩）先生的《关于 股份减持的告知函》：徐农先生因个人资金需求，拟通过大宗交易方式减持其通 过混沌天成 18 号间接持有的公司股份合计不超过 2,212,155 股（含本数），拟减 持股份占公司总股本 0.66%；Michael Mingyan Liu（刘明岩）先生因个人资金 需求，拟通过大宗交易方式减持其持有的公司股份合计不超过 4,457,094 股（含 本数），拟减持股份占公司总股本 1.34%。上述两位减持主体合计拟减持不超过 6,669,249 股（含本数）,合计拟减持股份占公司总股本 2.00%。 上述减持自公告披露之日起 15 个交易日之后的 3 月内（2026 年 2 月 4 日至 2026 年 4 月 ...

Core Viewpoint - The company announced a plan for significant share reductions by key shareholders, which will not affect the control of the company [1] Group 1: Shareholder Actions - Xu Nong, a key shareholder and president, plans to reduce his indirect shareholding by up to 221.22 million shares, representing 0.66% of the total share capital [1] - Michael Mingyan Liu, the chairman, intends to reduce his direct shareholding by up to 445.71 million shares, accounting for 1.34% of the total share capital [1] - Together, these shareholders aim to reduce their holdings by a total of up to 666.92 million shares, which is 2.00% of the total share capital [1] Group 2: Timing and Conditions - The reduction plan will be implemented within three months starting from 15 trading days after the announcement, specifically from February 4, 2026, to April 30, 2026 [1] - The total number of shares reduced within any consecutive 90-day period will not exceed 2.00% of the total share capital [1] Group 3: Reason for Reduction - The reason for the share reduction is stated as personal funding needs [1] - David Fan, a related party, will not participate in this reduction plan [1] Group 4: Control Implications - The planned share reductions will not lead to any change in the actual control of the company [1]

Group 1 - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total [1][3] - Among these, Baili Tianheng led with a fundraising amount of 3.731 billion yuan, followed by Dize Pharmaceutical with 1.773 billion yuan, and Lukang Pharmaceutical with 1.187 billion yuan [3] - The fundraising purposes vary significantly among the companies, with Baili Tianheng and Dize Pharmaceutical focusing on innovative drug research and development [5][6] Group 2 - Baili Tianheng plans to use all raised funds for innovative drug R&D, specifically for platforms related to ADC drugs, multi-specific antibodies, and nuclear medicine [5] - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization, marking it as the first unprofitable company to complete refinancing under the "Science and Technology Innovation Board" framework [5] - Other companies like Aibo Medical and Sanyou Medical have different focuses, with Aibo primarily investing in production line construction and Lukang in high-end formulation manufacturing [5][6] Group 3 - Only two of the eight companies reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and net profit [7] - Baili Tianheng experienced the largest decline in performance, with a revenue drop of 63.52% and a net loss of 4.95 billion yuan, attributed to decreased sales and increased R&D expenses [7][8] - In contrast, Baili Tianheng reported a substantial revenue increase in Q3, driven by successful collaborations and milestone payments [8] Group 4 - Baili Tianheng has also announced plans to issue debt financing tools with a scale of up to 10 billion yuan for various purposes, including R&D and debt repayment [4] - Dize Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] - The competitive landscape in the pharmaceutical industry is intensifying, necessitating continuous investment for companies to maintain technological leadership and market position [8]

Core Viewpoint - The company is in the early stages of expanding its overseas business, particularly in the U.S. market, which is showing significant growth potential [1] Group 1: Business Performance - The company's U.S. business has achieved impressive performance, with revenue growth of 83.04% year-on-year in the first three quarters of 2025 [1] - The U.S. market is becoming a crucial engine for the company's international business growth [1] Group 2: Market Development - The company's overseas business is still in the early market development phase, especially in the U.S. market, which is transitioning from minimal to more substantial operations [1]

Core Viewpoint - The actual controller of the company and their concerted actions are reducing their holdings based on personal financial needs and planning, which does not indicate a lack of confidence in the company [1] Group 1: Company Performance - The company reported a revenue of 391.47 million yuan for the first three quarters of 2025, representing a year-on-year growth of 17.65% [1] - The net profit attributable to the parent company reached 61.98 million yuan, showing a significant year-on-year increase of 623.19% [1] Group 2: Management and Strategy - The actual controller and management team are actively monitoring the company's operations and the pressures faced in the industry [1] - The company is implementing various measures to enhance its operational and profitability levels, achieving commendable performance [1]

Core Viewpoint - Shanghai Sanyou Medical Instrument Co., Ltd. has signed a strategic cooperation and distribution agreement with CGBio Co., Ltd. to obtain exclusive distribution rights for the Novosis product in mainland China, which is expected to enhance the company's product line and competitive strength in the orthopedic biomaterials sector [2][4][20]. Agreement Overview - The agreement grants Sanyou Medical exclusive and non-transferable rights to procure, import, market, distribute, sell, promote, and conduct other commercial activities related to the Novosis product in mainland China for a period of six years, starting from the date the product receives medical device registration from the National Medical Products Administration of China [2][9][10]. Product Details - Novosis is a biomaterial product containing recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, designed for synthetic bone grafting. It is produced using genetically engineered E. coli and is packaged with a disposable syringe and needle [3][11][19]. - The product is known for its strong osteoconductive and osteoinductive properties, promoting the formation of new bone and cartilage, and is widely used in various surgical repairs, including spinal fusion and trauma [12][20]. Impact on the Company - The exclusive distribution rights for Novosis will enrich Sanyou Medical's product offerings and enhance its position in the orthopedic biomaterials market, providing comprehensive surgical solutions for patients and doctors, which is expected to positively impact the company's operations [4][20]. - Sanyou Medical is recognized as a leading company in the development, production, and sales of orthopedic implant consumables, with strong market sales channels and a rich customer base [18]. Partner Company Overview - CGBio Co., Ltd. is a South Korean company specializing in the research, production, and sales of medical device biomaterials, with significant expertise in various core technologies related to tissue regeneration and implant design [18].

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with CGBio, granting exclusive rights to distribute Novosis products in mainland China, which is expected to enhance its competitive strength in the orthopedic biomaterials sector [1][3]. Group 1: Agreement Details - The agreement was signed on December 2, 2025, and grants the company exclusive, non-transferable rights for procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1]. - The authorization is valid for six years from the date the products receive medical device registration from the National Medical Products Administration of China [1]. Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [2]. - The product is produced through genetic engineering from human rhBMP-2 cDNA and is designed to promote new bone formation with strong osteoconductive and osteoinductive properties [2]. - It is widely used in various surgical repair and reconstruction applications, including spinal fusion, limb trauma, and oral surgery [2]. Group 3: Strategic Impact - Acquiring exclusive distribution rights for Novosis products will enrich the company's product line and enhance its positioning in the orthopedic biomaterials market, providing comprehensive surgical solutions for patients and doctors [3]. - This move is expected to positively impact the company's operations and overall competitiveness in the industry [3].

上海三友医疗器械股份有限公司 关于公司与韩国细基生物株式会社签署 战略合作和经销协议的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 协议概述：上海三友医疗器械股份有限公司（以下简称"公司"或"三 友医疗"）与韩国细基生物株式会社（CGBio Co., Ltd.）（以下简称"CGBIO"或 "韩国细基生物"）于 2025 年 12 月 2 日签署了《战略合作和经销协议》（以下简 称"合作协议"），根据协议约定：在中国大陆地区，CGBIO 对协议产品 Novosis 产品（以下简称"经销产品"）授予三友医疗进行采购、进口、营销、分销、销 售、推广、要约销售、促成销售及其他商业化活动的独家、不可转让权利。授权 有效期为经销产品获得中国国家药品监督管理局（以下简称"中国药监局"）颁 发医疗器械注册证之日起六年。 证券代码：688085 证券简称：三友医疗 公告编号：2025-088 协议对方名称：细基生物株式会社（CGBio Co., Ltd.） 性质：股份有限公司 （一）协议对方的基本情况 一、协 ...

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with CGBio, granting exclusive rights to distribute Novosis products in mainland China for six years after obtaining regulatory approval [1][3]. Group 1: Agreement Details - The agreement allows the company to engage in procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1]. - The exclusivity of the rights is contingent upon the product receiving a medical device registration certificate from the Chinese National Medical Products Administration [1]. Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [2]. - The product is produced using genetically engineered E. coli to efficiently produce rhBMP-2, which promotes new bone formation and has strong osteoconductive and osteoinductive properties [2]. - rhBMP-2 is widely used in various surgical repair and reconstruction applications, including spinal fusion, limb trauma, and oral surgery [2]. Group 3: Strategic Impact - Acquiring exclusive distribution rights for Novosis will enhance the company's product line and strengthen its position in the orthopedic biomaterials sector, providing comprehensive surgical solutions for patients and doctors [3]. - This development is expected to positively impact the company's overall competitiveness and operational performance [3].